Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Extemporaneous Indomethacin Oral Suspension Prepared from Injectable Ampules for Therapy in Premature Infants and Pediatric Patients

Author(s):  de Lafuente Yanina, García Mónica Cristina, Jiminez-Kairuz Alvaro

Issue:  Jul/Aug 2019 - Volume 23, Number 4
View All Articles in Issue

Page(s):  324-331

Extemporaneous Indomethacin Oral Suspension Prepared from Injectable Ampules for Therapy in Premature Infants and Pediatric Patients Page 1
Extemporaneous Indomethacin Oral Suspension Prepared from Injectable Ampules for Therapy in Premature Infants and Pediatric Patients Page 2
Extemporaneous Indomethacin Oral Suspension Prepared from Injectable Ampules for Therapy in Premature Infants and Pediatric Patients Page 3
Extemporaneous Indomethacin Oral Suspension Prepared from Injectable Ampules for Therapy in Premature Infants and Pediatric Patients Page 4
Extemporaneous Indomethacin Oral Suspension Prepared from Injectable Ampules for Therapy in Premature Infants and Pediatric Patients Page 5
Extemporaneous Indomethacin Oral Suspension Prepared from Injectable Ampules for Therapy in Premature Infants and Pediatric Patients Page 6
Extemporaneous Indomethacin Oral Suspension Prepared from Injectable Ampules for Therapy in Premature Infants and Pediatric Patients Page 7
Extemporaneous Indomethacin Oral Suspension Prepared from Injectable Ampules for Therapy in Premature Infants and Pediatric Patients Page 8

Download in electronic PDF format for $75

Abstract:  Indomethacin is used for off-label prescription for the treatment of patent ductus arteriosus in premature infants. In Argentina, indomethacin is only available as a suppository, dermic cream, injectable ampules, and delayed-release capsules. Aiming to improve pediatric treatment and minimize the risk associated with improper dosage, this work focused on the development of an extemporaneous 0.2% indomethacin oral suspension, starting from the commercially injectable formulation. Two 150-mL batches of suspension were prepared using Generally Recognized as Safe excipients. The suspensions were stored for 17 days at room temperature. Physical stability, morphological analysis of suspended particles, sedimentation volume, easy re-suspension, and dynamic viscosity were studied. The indomethacin content, dissolution studies, and microbiological attributes of nonsterile pharmaceutical products were also evaluated. After 17 days of storage, the suspension was easily re-dispersed after 15 seconds of the hand-shaking technique. There were no detectable changes in color, odor, and/or flavor. The suspension showed minimal changes in pH, viscosity, shape, and mean size of the suspended indomethacin particles. The content uniformity and drug dissolution remained within the acceptable range during storage. This oral liquid suspension is an interesting alternative to be prepared by hospital pharmacy services for optimizing the pediatric treatment of patent ductus arteriosus.

Related Keywords: Yanina de Lafuente, PharmD, Mónica Cristina García, PhD, Alvaro Jiminez-Kairuz, PhD, indomethacin, nonsteroidal anti-inflammatory drug, NSAID, patent ductus arteriosus, neonates, physical stability, chemical stability

Related Categories: PEDIATRICS, PEER-REVIEWED, STABILITIES, COMPATIBILITIES, CARDIOLOGY

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Extemporaneous Indomethacin Oral Suspension Prepared from Injectable Ampules for Therapy in Premature Infants and Pediatric Patients
de Lafuente Yanina
, García Mónica Cristina, Jiminez-Kairuz Alvaro
Jul/Aug 2019
Pg. 324-331

Pediatric Compounding: Coloring Outside the Lines
Preckshot John
Jan/Feb 2001
Pg. 6-8

Stability Issues for Compounding Extemporaneously Prepared Oral Formulations for Pediatric Patients
Schotik Debora
Jan/Feb 2001
Pg. 9-12

Formulation Development and Stability Testing of Extemporaneous Suspension Prepared From Dapsone Tablets
Kaila Nitin
, El-Ries Mohamed, Riga A, Alexander Kenneth S, Dollimore D
May/Jun 2003
Pg. 233-239

Indomethacin 1-mg/mL Injection
Allen Loyd V Jr
Sep/Oct 2013
Pg. 419

Indomethacin 2-mg/mL Oral Liquid
Allen Loyd V Jr
Nov/Dec 2006
Pg. 458

Compounding for the Pediatric Patient
Allen Loyd V Jr
Mar/Apr 1997
Pg. 84-86

Stability of Extemporaneously Prepared Hydroxycarbamide Oral Suspensions
Kabiche Djamila
, Balde Issa-Bella, Majoul Elyes, Kabiche Sofiane, Bourguignon Elodie, Fontan Jean-Eudes, Cisternino Salvatore, Schlatter Joel
Mar/Apr 2017
Pg. 160-163

Physicochemical Stability of the Extemporaneous Ibuprofen Oral Suspension in "Wagner" Base
Spennacchio Antonio
, Lopedota Angela, la Forgia Flavia, Fontana Sergio, Franco Massimo, Denora Nunzio
Jan/Feb 2023
Pg. 72-77

Extemporaneous Compounding of Oral Acitretin Suspension for Pediatric Patient with Generalized Pustular Psoriasis
Choo Winnie
Jan/Feb 2016
Pg. 6-10

Treatment of Pain with a Topically Applied Combination of Indomethacin and Piroxicam
Vetter Eric R
, Curtis Lawrence
May/Jun 2002
Pg. 189-192

Indomethacin 2% in Pluronic Lecithin Organogel
Allen Loyd V Jr
Nov/Dec 2008
Pg. 543

Cyclobenzaprine Hydrochloride 1%, Dextromethorphan Hydrobromide 10%, Guaifenesin 10%, and Indomethacin 20% Penetrating Gel
Allen Loyd V Jr
Nov/Dec 2008
Pg. 541

Indomethacin 1% Topical Gel
Allen Loyd V Jr
Jul/Aug 2022
Pg. 325-326

Formulation and Accelerated Stability Studies for an Extemporaneous Suspension of Amiodarone Hydrochloride
Alexander Kenneth S
, Thyangarajapuram N
Sep/Oct 2003
Pg. 389-393

Pluronic Lecithin Organogel for Local Delivery of Anti-Inflammatory Drugs
Frankum James
, Ramsay Dale, Das Nandita G, Das Sudip K
Mar/Apr 2004
Pg. 101-105

Indomethacin Gel
Allen Loyd V Jr
May/Jun 2016
Pg. 230

Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF pH4
Polonini Hudson
, da Silva Sharlene Loures, Brandão Marcos Antônio Fernandes, Bauters Tiene, De Moerloose Barbara, Ferreira Anderson de Oliveira
Nov/Dec 2018
Pg. 516-526

Case Report: Cocktail Dosing in a Premature Infant with a History of Cholestasis
Fields Shannon W
Jan/Feb 2007
Pg. 26-27

Menopausal Women's Access Path to Bioidentical Hormone Replacement Therapy: An Exploratory Study
Moro Doris
, Young Wendy, Stein Richard, Isaac Winston, Goodman Deborah
Mar/Apr 2010
Pg. 165-170

Return to Top